Objective: To perform per-protocol analysis of data obtained from the NICHD vitamin D pregnancy study published by Hollis et al., which found via intent-to-treat analysis that 4000IU ... sufficiency in women and…
combinations was inferior to AmBisome in both the intention-to-treat and per-protocol populations. All the combinations demonstrated excellent overall efficacy, were well tolerated and safe and could
differ between the two groups after the 3-month intervention. Results of per-protocol analysis were comparable with the findings of the ITT analysis. Results showed that the eHealth intervention
hydroxyvitamin D, 1,25-dihydroxyvitamin D, and cathelicidine. Besides intention-to-treat analyses, per-protocol analyses were performed at twelve (n=63 in the vitamin ... intention-to-treat analyses, but were higher in…
higher recoveryRate Ratio (RR) than placebo in modified Intention to Treatment (mITT) set andin Per-Protocol (PP) set, respectively. The median difference in TTCI_S was 3.5days between
IIEF: International Index of Erectile Function; IP: Investigational Products; ITT: Intention-To-Treat; PP: Per-Protocol; SD: Standard Deviation; SGPT: Serum Glutamic Pyruvic Transaminase; WHO: World Health Organization
referral practice in Houston, Texas. The tin-117m colloid was administered per-protocol to 14 client-owned dogs with radio graphically confirmed grade 3 OA in one or both elbow
sample size of 40 patients involving moderate and severe COPD cases was factored for per-protocol analyses with P < 0.05 considered as statistically significant. A concurrent study analysis
13Curea breath testing while other ones discontinued because of any intolerable adverse events. The per-protocol eradication rates achieved with OAC regimen was significantly higher than the OAO treatment protocol
equivalence between a generic and an innovator product is usually based on the observed per-protocol (PP) population. However, missing data and non-compliance are post-randomization intercurrent events
equivalence between a generic and an innovator product is usually based on the observed per-protocol (PP) population. However, missing data and non-compliance are post-randomization intercurrent events
equivalence between a generic and an innovator product is usually based on the observed per-protocol (PP) population. However, missing data and non-compliance are post-randomization intercurrent events
randomized, 257 completed the study and 256 (128 vs. 128) were included in the per-protocol set. Sixty five individual adverse events (AE) were reported in 47 of 260 patients
patients in the intent-to-treat (ITT) and 94.7% in the per-protocol (PP) populations. Microbiological success rate at TOC in ITT and PP populations were 82.6% and 89.5%, respectively
patients in the test group achieved SVR12 (98.33% (CI: 91.14–99.71%). The per-protocol (PP) analysis, excluding patients who dropped-out before collecting their final result, showed that
week 12 after cessation of therapy, the SVR12 was 97.1 % (8128//9276) by per-protocol analysis. There were 548 (5.7%) patients discontinuing the therapy prematurely. In the real-world first
preferences, growth and nutritional variables. Results: Sixty-one subjects completed both challenges in the per-protocol groups. The new formula was non-inferior to Nutramigen regarding allergic symptoms of reactivity
identified 39 studies including a total of 1640 patients. The overall technical success, per-protocol clinical success and complications rates with 95 % confidence interval were
outcome data were analysed by Cox proportional hazard models in intention-to-treat and per-protocol analyses according to the statistical analysis plan deposited at the Data Safety Monitoring Board
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.